Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis

Virus Research

Volumn 153, Issue 1, 2010, Pages 113-120

  Sánchez Burgos, Gilma ^a   Ramos Castañeda, José ^b   Cedillo Rivera, Roberto ^a   Dumonteil, Eric ^c,d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^d TULANE UNIVERSITY   (United States)

Author keywords

Bioinformatics; Dengue virus; Epitopes

Indexed keywords

EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN DETECTION; ARTICLE; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; EPITOPE MAPPING; IMMUNOGENICITY; INFECTION RESISTANCE; INTERFERON PRODUCTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION;

DENGUE VIRUS; MUS;

EID: 77956210124     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.07.014     Document Type: Article

References (34)

1. Al-Attiyah R., Mustafa A.S. Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th-1 cell peptides in the 24kDa secreted lipoprotein (Lppx) of Mycobacterium tuberculosis. Scand. J. Immunol. 2004, 59:16-24.
2. Anandarao R., Swaminathan S., Khanna N. The identification of immunodominat linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides. Virus Res. 2005, 112:60-68.
3. Amexis G., Young N.S. Multiple antigenic peptides as vaccine platform for the indution of humoral respnses against dengue-2-viruses. Viral Immunol. 2007, 20:657-663.
4. Bashyam H.S., Green S., Rothman A.L. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J. Immunol. 2006, 176:2817-2824.
5. Crooks G.E., Hon G., Chandonia J.M., Brenner S.E. WebLogo: a sequence logo generator. Genome Res. 2004, 14:1188-1190.
6. Churdboonchart V., Bhamarapravati N., Peampramprecha S., Sirinavin S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 1991, 44:481-493.
7. De Groot A.S. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov. Today 2006, 11:203-209.
8. De Groot A.S., Saint-Aubin C., Bosma A., Sbai H., Rayner J., Martin W. Rapid determination of HLA B*07 ligands from the West Nile Virus NY99 genome. Emerg. Infect. Dis. 2001, 7:706-713.
9. DengueNet1 - WHO's Internet-Based System for the Global Surveillance of Dengue Fever and Dengue Haemorrhagic Fever (Dengue/DHF). http://www.who.int/csr/disease/dengue/impact/en/index.html.
10. Donnes P., Kohlbacher O. Integrated modeling of the major events in the MHC class I antigen processing pathway. Protein Sci. 2005, 14:2132-2140.
11. Gagnon S.J., Zeng W., Kurane I., Ennis F.A. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocite clones. J. Virol. 1996, 70:141-147.
12. Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 2006, 19:429-436.
13. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 1998, 11:480-496.
14. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
15. Herrera-Najera C., Aguilar R.P., García F.X., Sierra M.J.R., Dumonteil E. Mining the Leishmania genome for novel antigens and vaccine candidates. Proteomics 2009, 9:1293-1301.
16. Jiang L., Zhou J.M., Yin Y., Fang D.Y., Tang Y.X., Jiang L.F. Selection and identification of B-cell epitope on NS1 protein of dengue virus type 2. Virus Res. 2010, 150:49-55.
17. Khan A.M., Miotto O., Heiny A.T., Salmon J., Srinivasan K.N., Nascimento E.J.M., Marques E.T.A., Brusic V., Tan T.W., August J.T. A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cellular Immunol. 2006, 244:141-147.
18. Khan A.M., Miotto O., Nascimento E.J.M., Srinivasan K.N., Heiny A.T., Zhang G.L., Marques E.T., Tan T.W., Brusic V., Salmon J., August T. Conservation and variability of dengue virus proteins: implications for vaccines design. Plos Negl. Trop. Dis. 2008, 2. e272, 1-14.
19. Kurane I., Okamoto Y., Dai L.C., Zeng L.L., Briton M.A., Ennis F.A. Flavivirus-cross-reactive HLA-DR15-restricted epitope on NS3 recognized by human CD4+CD8- cytotoxic T lymphocyte clones. J. Gen. Virol. 1995, 76:2243-2249.
20. Larsen M.V., Lundegaard C., Lamberth K., Buus S., Brunak S., Lund O., Nielsen M. An integrative approach to CTL epitope prediction: combined algorithm integrating MHC class I binding, TAP transport efficiency and proteasomal cleavage predictions. Eur. J. Immunol 2005, 35:2295-2303.
21. Leclerc C., Dériaud E., Megret F., Briand J.P., Van-Regenmortel M.H.V., Deubel V. Identification of helper T cell epitopes of dengue virus E-protein. Mol. Immunol. 1993, 7:613-625.
22. Mangada M.M., Ennis F.A., Rothman A.L. Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. J. Immunol. Methods 2004, 284:89-97.
23. Moutaftsi M., Peters B., Pasquetto V., Tschrke D.C., Sidney J., Bui H.H., Grey H., Sette A. A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to Vaccinia virus. Nat. Biotechnol. 2006, 24:817-819.
24. Roehrig J.T. Antigenic structure of flavivirus proteins. Adv. Virus Res. 2003, 59:141-175.
25. Rothman A.L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 2004, 113:946-951.
26. Sánchez-Burgos G.G., López-Alvarado M.A., Castañeda-Desales D., Ruiz-Gómez J., Ramos-Castañeda J. Prevalence of neutralizing antibodies to dengue virus serotypes in university students from Tabasco, Mexico. Salud Publica Mex. 2008, 50:362-366.
27. Schafer J.R.A., Jesdale B.M., George J.A., Kouttab N.M., De Groot A.S. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm EpiMatrix. Vaccine 1998, 16:1880-1884.
28. Trirawatanapong T., Chandran B., Putnak R., Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 1992, 116:139-150.
29. Vázquez S., Guzmán M.G., Guillen G., Chinea G., Pérez A.B., Pupo M., Rodriguez R., Reyes O., Garay H.E., Delgado I., García G., Alvarez M. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002, 20:1823-1830.
30. Wahala W.M.P.B., Kraus A.A., Haymore L.B., Accavitti-Loper M.A., de Silva A. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392:103-113.
31. Wen J.S., Jiang L.F., Zhou J.M., Yan H.J., Fang D.Y. Computational prediction and identification of dengue virus-specific CD4+ T-cell epitopes. Virus Res. 2007, 132:42-48.
32. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospect for a dengue virus vaccines. Nat. Rev. Microbiol. 2007, 5:518-528.
33. Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., Prestwood T.R., Sette A., Shresta S. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 2009, 182:4865-4873.
34. Yeh I., Hanekamp T., Tsoka S., Karp P.D., Altman R.B. Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res. 2004, 14:917-924.